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Dimeric benzoboroxoles for targeted activity
against Mycobacterium tuberculosis†
Collette S. Guy, a,b Kathryn Murray, b Matthew I. Gibson *b,c and
Elizabeth Fullam *a
Dimeric benzoboroxoles that are covalently linked by a short scaﬀold enhance selective anti-tubercular
activity. These multimeric benzoboroxole compounds are capable of engaging the speciﬁc extracellular
Mycobacterium tuberculosis glycans, do not lead to the evolution of resistance and bypass the need to
cross the impermeable mycobacterial cell envelope barrier.
Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a
major global health problem with over 10 million new cases of
TB and 1.6 million deaths reported by the World Health
Organisation in 2017.1 The rapid emergence of drug resistance
has led to an alarming increase in both multidrug-resistant
(MDR)-TB and extensively drug-resistant (XDR)-TB rendering
the current frontline TB therapeutic regimens ineﬀective.1
Clearly there is an urgent need to develop innovative thera-
peutic interventions that have distinct mechanisms of action
to reduce the global TB burden.
The Mtb cell envelope is distinct from other microorganisms
and contributes to the survival and virulence of this pathogen.2–4
The complex lipids and glycans within the cell envelope provide
a formidable, impermeable barrier to antibiotics that further
complicates eﬀorts to eradicate TB.2–5 The architecture of the
Mtb cell envelope comprises a complex macromolecular core
consisting of peptidoglycan linked to arabinogalactan that in
turn is covalently attached to long-chain mycolic acids (mAGP
complex).3 Additional non-covalently linked lipids and lipogly-
cans are interspersed within the mycolate layer of the mAGP
complex to form an outer, waxy, ‘mycomembrane’.2–4
The current anti-tubercular agents are lethal to Mtb
through modulation of well-defined intracellular pathways.6
In particular, targeting key enzymes that are involved in the
synthesis and assembly of the Mtb cell envelope has proved to
be a highly eﬀective strategy for the development of new TB
therapeutics,5,6 highlighted by the clinical use of the front-
line antitubercular agents isoniazid and ethambutol and
several second-line drugs that include cycloserine and
ethionamide.7–9
Recent studies have shown that an alternative anti-tubercu-
lar approach is possible through the direct capture of the
structurally unique mycobacterial extracellular glycans with
multimeric boronic acids.10 Specifically, two boronic acid
units separated by a short poly(ethylene glycol) (PEG) linker
were found to be optimal for antimycobacterial selectivity and
potency.10 This concept exploits the vulnerability of the essen-
tial mycobacterial cell wall with the advantage that the antimy-
cobacterial agent does not need to cross the Mtb cell envelope
and avoids one of the major obstacles in the development of
new TB therapeutics.
Multimeric boronic acids have emerged as synthetic
receptors for the specific detection of glycans.11 The nature of
both the boronic acid and the scaﬀold linker can be tuned
and modulated to enable selective glycan recognition.11
Benzoboroxoles are water soluble heterocyclic-modified
boronic acids,12,13 and in addition to their role as glycan
sensors have also emerged as an interesting class of bio-
molecules that have a range of potent biological activities
against a range of diseases.14–16 This includes potent activity
and selectivity against Mtb, and the GlaxoSmithKline (GSK)
aminobenzoboroxole analogue (GSK656) that targets leucyl-
tRNA synthetase is a promising anti-tubercular candidate that
has been progressed into phase II clinical trials.17,18
Here, we therefore replaced the boronic acid units to gene-
rate a panel of dimeric benzoboroxoles to promote the inter-
action with the unique extracellular mycobacterial glycans.
These compounds have excellent, selective activity for myco-
bacteria, including the Mtb pathogen, are capable of complex-
ing to Mtb glycans without resulting in the evolution of resis-
tance and have a distinct mode of action to monomeric benzo-
boroxole analogues.
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Results and discussion
Dimeric benzoboroxoles were synthesised such that the inter-
boroxole distance was systematically varied by the use of
various oligo(ethylene glycol) diamine linkers (Fig. 1). Dimeric
benzoboroxoles were obtained in one step by reaction of ben-
zoboroxole-carboxylic acid (1-hydroxy-1,3-dihydro-2,1-benzoxa-
borole-6-carboxylic acid) 6 with the diamines using 1.1 equiv.
PyBOP as the coupling reagent (Scheme S1, ESI†). Following
purification all compounds were characterised by 1H and 13C
NMR and mass spectrometry confirming successful coupling
and high purity of 2–5 (Fig. S3–12, ESI†). An Alizarin red based
assay confirmed carbohydrate-benzoboroxole binding with
similar trends and aﬃnities observed for the carbohydrates
with the monomeric benzoboroxole 1 and the dimeric ana-
logues 2–4 (Fig. S1, ESI†).
Next, the panel of dimeric benzoboroxole compounds (2–5)
was evaluated for antibacterial activity using the resazurin
reduction assay19 to determine the minimum inhibitory con-
centrations (MIC) against Mtb, Mycobacterium bovis BCG and
Mycobacterium smegmatis and the Gram-negative strains
Escherichia coli and Pseudomonas putida. The monomeric ben-
zoboroxole compound 1, which is known to target leucyl-tRNA
synthetase (LeuRS),18,20 had micromolar potencies with
similar MIC values for all of the mycobacterial and Gram-nega-
tive strains evaluated (Table 1, Fig. 2). However, by changing
the benzoboroxole to a dimeric unit (2–4) a large increase in
selectivity for mycobacteria was observed (Table 1, Fig. 2).
Whilst the MIC values of the dimeric benzoboroxoles 2–4
increased compared to mono-benzoboroxole 1 for all strains
(Table 1, Fig. 2), there was a marked increase in the MICs of
2–4 against the Gram-negative strains that was not observed
for mycobacteria. The observed change in the MIC profile of
the dimeric benzoboroxoles 2–4 compared to the monomeric
benzoboroxole unit 1 confirms that selectivity for mycobacteria
is controlled by the dimeric presentation. Dimeric benzoborox-
ole 5, which contains a longer scaﬀold linker length (PEG22)
between the boroxole pharmacophores, resulted in a much
higher MIC (25 mM) than those with 0–3 PEG units
(0.39–6.25 mM) (2–4) against mycobacteria and loss of speci-
ficity with similar potencies observed for the Gram-negative
organisms E. coli and P. putida (Table 1, Fig. 2). These obser-
vations agree with our previous study using dimeric boronic
acids which also found that short linker lengths were crucial
for optimising anti-mycobacterial activity and selectivity.10
Cytotoxicity evaluation of dimeric benzoboroxoles 2–4
against human lung epithelial A549 cells showed that com-
pounds 2–4 were not toxic at concentrations >10 mM (3) and
>5 mM (2, 4), which were the highest concentrations possible
to test due to solubility limits and toxicity levels of DMSO
(Table 2). Importantly, evaluation of compounds 2–4 against
erythrocytes did not result in haemolysis or agglutination at
concentrations above 10 mM (Table 2). Combined, these
results demonstrate that dimeric benzoboroxoles 2–4 have a
higher selectivity for mycobacteria than mammalian cells.
Fig. 1 Synthesis of dimeric benzoboroxoles (2–5). (A) Synthetic strategy
(Et3N: triethylamine; PyBOP: benzotriazol-1-yl-oxytripyrrol-idinopho-
sphonium hexaﬂuorophosphate); (B) compounds used in this study.
Table 1 Bacterial susceptibility to benzoboroxoles 1–5
MIC mycobacteria (mM)
MIC Gram-
negative (mM)
Mtb M. bovis BCG M. smegmatis E. coli P. putida
1 0.625 0.125 0.078–0.125 0.125 0.125
2 6.25 0.78 0.78 >12.5 >12.5
3 1.56 0.78 0.39–0.78 >12.5 >12.5
4 1.56 1.56 0.39–0.78 >12.5 >12.5
5 >25 >25 25 >25 >25
Fig. 2 Antimicrobial activities of benzoboroxoles 1–5.
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Boron containing molecules are known to inhibit
β-lactamases that otherwise degrade β-lactam antibiotics and
their combined use has proved to be a useful strategy to
restore the activity of this important class of antibiotics.21,22
To determine whether dimeric benzoboroxoles also function
in this manner we used a checkerboard assay to evaluate the
potential interactions of compounds 3 and 4 with the β-lactam
meropenem on Mtb. To quantify the interactions between
these compounds the sum of the fractional inhibitory index
(∑FIC) was calculated for each combination (Table 3).23 For
meropenem, the ∑FIC was found to be 2 and 1.5 for com-
pounds 3 and 4 respectively indicating no synergistic or antag-
onistic action with the β-lactam, in contrast to the calculated
∑FIC of 0.3 for meropenem in combination with the
β-lactamase inhibitor sulbactam. These results provide evi-
dence that the multimeric benzoboroxoles 3 and 4 are not
recognised by β-lactamase targets in Mtb suggesting that these
compounds have a unique mechanism of action. In addition,
the interaction of benzoboroxoles 3 and 4 with the front-line
TB drug rifampicin was also evaluated and again no synergistic
nor antagonistic behaviour was observed with the ∑FIC calcu-
lated as 2 for both compounds (Table 3).
To provide more information of the mechanism of action
and attempt to elucidate the target of the dimeric benzoborox-
oles, we attempted to generate spontaneous resistant mutants
of M. bovis BCG at 5× MIC of either the monomer 1 or the
dimeric compound 3. Interestingly, we were unable to generate
resistant mutants against the dibenzoboroxole (3) which
further supports the hypothesis that these molecules have a
distinct mode of action. In contrast, resistant mutants were
derived against mono-benzoboroxole (1) with a frequency of
five resistant mutants (BRX1–BRX5) generated from 1 × 108
cells. Whole genome sequencing of each resistant strain
(BRX1–BRX5) revealed non-synonymous mutations in 5 gene
loci compared to the wild-type M. bovis BCG reference strain
(Table 4). In particular, we identified non-synonymous poly-
morphisms in the leuS gene (Table 4) in each resistant strain
(BRX1–5), which encodes for the leucine-tRNA ligase (LeuS)
and is reported to be a target of monomeric benzoboroxoles,
including GSK656.18 To establish whether there is cross-resis-
tance of the five mono-benzoboroxole M. bovis BCG mutants
(BRX1–5) to the dimeric benzoboroxoles 2–4 we re-evaluated
the MICs of 1–4 against these mutant strains. As expected, the
MIC of mono-benzoboroxole 1 increased by 10–20 fold for
each mutant (Table 5), whereas the MIC of the dimeric benzo-
boroxoles (2–4) were found to be comparable with the MICs
that had been determined previously for wild-type M. bovis
BCG (Table 5). These results provide robust evidence that the
dimeric benzoboroxoles have a distinct molecular target com-
Table 2 Cytotoxicity testing of compounds 2–4
Compound
A549 Red blood cells
MIC99 (mM) Haemolysis (%) Agglutination
2 >5 1.1 ND
3 >10 0.75 ND
4 >5 1.25 ND
ND – no agglutination detected.
Table 3 MIC proﬁles against Mtb and corresponding interaction
proﬁles in combination with meropenem and rifampicin
Compound MIC (mM)
Interaction profile
with meropenem
Interaction profile
with rifampicin
∑FICa Outcome ∑FICa Outcome
3 1.56 2 Additive 2 Additive
4 1.56 1.5 Additive 2 Additive
Sulbactam 0.134 0.313 Synergistic — —
a Fractional inhibitory concentrations (FICs) were calculated by use of
the formula as described previously.24–26
Table 4 Single nucleotide polymorphisms in Mycobacterium bovis BCG spontaneous mutants to benzoboroxole 1
M. bovis BCG
chromosome positiona Mutation-type Codon change
Amino acid
change Gene Strainb
74515 Non-synonymous tAc/tGc Y435C leuS BRX3
74521 Non-synonymous aCc/aTc T437I leuS BRX5
74527 Non-synonymous gCa/gAa A439E leuS BRX2
BRX4
74757 Non-synonymous Aaa/Gaa K516E leuS BRX1
2434500 Codon change plus codon insertion acg/acCACg T258TT trpD BRX5
3627670 Non-synonymous aCc/aAc T245N BCG_3323c BRX2
BRX3
BRX4
3663833 Non-synonymous aCc/aAc T245N BCG_3359c BRX2
BRX3
BRX4
4112296 Frame shift ggt/ggGt G192G glpK BRX2
BRX3
BRX4
BRX5
aGenomic positions are relevant to M. bovis BCG Pasteur 1173P2 strain (NC_008769). b Five resistant mutants of M. bovis BCG were generated
against benzoboroxole 1 and referred to as BRX1, BRX2, BRX3, BRX4 and BRX5.
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pared to monomeric benzoboroxoles and that this does not
involve interaction with LeuS.
Finally, we used biolayer interferometry (BLI) to probe
whether the dimeric benzoboroxoles are able to specifically
recognise glycans that are located in the mycobacterial cell
envelope (Fig. S2 ESI†). A biotinylated benzoboronic acid (7)
was synthesised (Scheme S2, ESI† and Fig. 3) and immobi-
lised onto streptavidin-coated BLI sensors to ensure multi-
valent presentation of the glycan recognition units. Isolated
components of the mycobacterial cell envelope were assessed
for binding to the benzoboroxole sensors (Fig. 3). Of the
Mtb glycans that we evaluated the highest aﬃnity was
observed with the benzoboroxole sensor for the trehalose
containing glycolipids with a higher selectivity for trehalose
dimycolate (TDM) over trehalose monomycolate (TMM)
(Fig. 3). Benzoboroxoles are known to complex with hexo-
pyranosides and nonreducing glycopyranosides and our find-
ings are consistent with these results.12 Weak binding
aﬃnity towards arabinogalactan (AG) was observed and no
specific binding to other mycobacterial cell envelope com-
ponents was detected. This is in contrast to our previous
studies which found that a boronic acid functionalised BLI
sensor bound to TDM and TMM equally well but also had
high aﬃnity for AG as well as lipoarabinomannan (LAM) and
peptidoglycan (PG) components.10 These data confirm that
benzoboroxoles can engage with several components of the
mycobacterial cell wall and that this has a fatal impact on
mycobacterial cells.
Furthermore, we investigated whether the benzoboroxole
unit is able to recognise glycans that are associated with either
Gram-negative bacteria or mammalian cell surfaces. In these
experiments, no specific binding was observed with the Gram-
negative glycan lipopolysaccharide (LPS) or the mammalian
specific glycan monosialodihexosylganglioside (GM3). Overall,
these results may help to explain the apparent antimicrobial
selectivity of the dimeric benzoboroxoles which may be due to
the diﬀerences in how they target external mycobacterial
specific glycans.
Conclusions
In conclusion, we have demonstrated that dimeric benzoborox-
oles are selective antimycobacterial agents and are lethal to
Mtb via a diﬀerent mode of action from the monomeric benzo-
boroxole analogue (1). Further evidence to support and vali-
date our findings came from the resistance studies that con-
firms there is no cross-resistance between benzoboroxole 1
and the dimeric compounds 2–4. Importantly, we clearly
identified that we were unable to evolve resistance against the
dimeric benzoboroxole 3, which is advantageous in the
ongoing battle to combat antibiotic resistance. This study has
revealed that multimeric benzoboroxoles interact directly with
the mycobacterial trehalose glycolipids that are absent in the
human host. It is possible that the interaction of two benzo-
boroxoles, which are covalently linked via a short scaﬀold,
with these essential components of the Mtb cell envelope
impacts on the survival of mycobacteria. The ability to target
surface-exposed glycans directly bypasses the obstacle of the
mycobacterial cell envelope and the need to cross this
Table 5 MIC values against M. bovis BCG resistant mutants
MIC (mM)
WT BRX1 BRX2 BRX3 BRX4 BRX5
1 0.078–0.125 1.25–2.5 1.25 1.25–2.5 1.25 1.25–2.5
2 0.78 0.78 0.78 0.78 1.56 1.56
3 0.78 1.56 1.56 1.56 1.56 1.56
4 1.56 3.13 3.13 3.13 1.56 1.56
Fig. 3 Biolayer interferometry analysis of 3-carboxy benzoboroxole
functional sensor 7 against TDM (trehlaose dimycolate, TMM (trehalose
monomycolate, LAM (lipoarabinomannan), LM (lipomannan), AG (arabi-
nogalactan), PG (peptidoglycan), LPS (lipopolysaccharide), GM3 (glycan
monosialodihexosylganglioside).
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impermeable barrier and may guide the design of an entire
new class of highly selective anti-mycobacterial agents.
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